Login to Your Account



Amarin Stock Drops on FDA’s Lipid Biomarker Sea Change

By Catherine Shaffer
Staff Writer

Thursday, October 17, 2013
Shares in Amarin Corp. plc fell 61 percent Thursday following Wednesday’s surprise vote by the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommending against approval of the firm’s marketed fish oil-derived lipid-lowering drug Vascepa in a supplemental indication.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription